BioCardia, Inc. Common Stock vs. Halozyme Therapeutics, Inc.
BioCardia, Inc. Common Stock and Halozyme Therapeutics, Inc. are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| BCDA | HALO | |
|---|---|---|
| Market Cap | $15.00 million | $12.21 billion |
| Revenue (TTM) | — | $1.66 billion |
| Net Income (TTM) | — | $413.60 million |
HALO leads on 1 of 1 size & scale factors.
Valuation
| BCDA | HALO | |
|---|---|---|
| P/E Ratio | — | 31.10 |
| Price / Book | — | 85.09 |
| Price / Sales | — | 7.34 |
BCDA and HALO split the valuation factors evenly.
Profitability
| BCDA | HALO | |
|---|---|---|
| Net Margin | — | 24.86% |
| Return on Equity | — | 288.13% |
BCDA and HALO split the profitability factors evenly.
Risk & Sentiment
| BCDA | HALO | |
|---|---|---|
| Short Interest | 0.00% | 9.79% |
BCDA leads on 1 of 1 risk & sentiment factors.
Dig deeper: BCDA overview, BCDA financials, HALO overview, HALO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.